Semaglutide can lower blood sugar and body weight, but evidence of cardiovascular protection is broadening its role beyond weight loss and highlighting the importance of careful long-term monitoring.
Semaglutide began as a treatment for type 2 diabetes, but its wider visibility as a weight-loss medicine has obscured what it actually does and where it fits in care. The drug mimics glucagon-like peptide-1, a hormone released after meals, helping the body release insulin when blood sugar is high while also slowing digestion and reducing appetite. That combination can lower glucose and body weight at the same time, which is why clinicians have come to see it as more than just another diabetes medicine. According to Cleveland Clinic and the NHS, semaglutide is used for type 2 diabetes, obesity and, in selected patients, cardiovascular risk reduction. It is available in the United States as once-weekly injections under the brand names Ozempic and Wegovy, and as a daily oral tablet, Rybelsus.
The practical differences between the forms matter. Rybelsus must be taken on an empty stomach with a small amount of water, then followed by a waiting period before food, coffee or other medicines. That makes it more convenient for some people and less forgiving for others. The injectable versions avoid the timing problem, but they come with their own routine and require patients to get comfortable with self-injection. Semaglutide is not usually the first drug prescribed for type 2 diabetes; metformin remains a common starting point, and semaglutide is generally added when blood sugar remains above target, weight is a major concern or there is established cardiovascular disease.
What has most changed the conversation is the evidence around heart protection. The SELECT trial, published in the New England Journal of Medicine and discussed by the American College of Cardiology, followed more than 17,000 adults with overweight or obesity and established cardiovascular disease, but without diabetes. It found that 2.4 mg of semaglutide cut the risk of major cardiovascular events, including heart attack, stroke and cardiovascular death, by about 20% compared with placebo over roughly three years. That result broadened interest in the drug beyond weight loss alone and strengthened the case for GLP-1 therapy in people with elevated cardiovascular risk.
For patients with type 2 diabetes, this cardiovascular benefit sits alongside earlier evidence that semaglutide can help reduce the risk of worsening kidney or heart disease in selected groups. The upshot is that the medicine can serve more than one purpose at once: lowering glucose, helping with weight reduction and, for some people, reducing cardiovascular risk. Even so, it does not replace standard treatments such as statins, blood pressure medication or lifestyle measures. In people with diabetes and heart disease, experts still treat semaglutide as part of a wider plan rather than a substitute for established therapies.
The side effects most people notice first are gastrointestinal. Nausea, constipation, burping, stomach upset and an early feeling of fullness are common, especially when treatment is started or the dose is increased. These symptoms often improve as the body adjusts, particularly when dose increases are gradual and meals are smaller and less fatty. Because the medicine slows digestion, many people find they need to stop eating sooner than before. With the tablet form, taking it incorrectly can blunt absorption and make it less effective.
Another consequence of rapid weight loss has become a frequent topic in clinics and on social media: changes in facial volume and looser skin. That effect is not unique to one brand. It appears when body fat falls quickly and is often more noticeable in older adults whose skin has less elasticity. There is no drug that restores lost facial fat. Slower weight loss near goal weight, enough protein, resistance exercise and time may help, but some people still choose cosmetic procedures to address the change.
Cost remains one of the biggest barriers. Brand-name semaglutide can run into four figures a month without coverage, and insurance decisions often depend on diagnosis, prior treatment history and the fine print of a plan. Coverage is generally stronger when the medicine is prescribed for type 2 diabetes or cardiovascular risk reduction than when it is used only for weight loss. Compounded semaglutide became widely available during shortages and is usually cheaper, but the FDA has warned about dosing errors and variable quality, so patients who use it need to be especially careful about the pharmacy and the exact dose. For anyone starting or continuing the drug, the key is to treat it as one part of long-term diabetes care, with lab follow-up, side-effect monitoring and a plan for what happens if treatment stops.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
